Clinical Report: Cost-Effective GLP-1 Access and Digital Solutions

Overview

Recent policy changes and digital solutions have significantly reduced the cost of GLP-1 medications in the U.S., making them more accessible to patients without insurance. However, early data indicate high discontinuation rates, highlighting challenges in sustaining long-term treatment.

Background

GLP-1 receptor agonists have demonstrated substantial weight loss in clinical trials, yet their high costs have historically limited access for uninsured patients. Recent shifts in pricing policies and the introduction of direct-to-consumer platforms have created new pathways for access, but the sustainability of treatment remains a concern.

Data Highlights

No numerical data available.

Key Findings

• GLP-1 medication prices have dropped to below $350 monthly due to federal pricing policy changes.
• Direct-to-consumer platforms have facilitated access, with Eli Lilly's LillyDirect reaching over 1 million patients in 2025.
• Over 50% of first-time semaglutide users discontinued treatment within 12 months, primarily due to cost and side effects.
• Only 34% of employers covered GLP-1s for obesity in 2024, indicating limited insurance support.
• Cash-pay channels do not contribute to insurance deductibles, leaving patients without cumulative financial protection.

Clinical Implications

Healthcare providers should be aware of the evolving landscape of GLP-1 access and the importance of ongoing support for patients starting therapy. Addressing the high discontinuation rates will require integrated care approaches that include financial, dietary, and behavioral support.

Conclusion

While recent changes have improved access to GLP-1 medications, the challenge now lies in ensuring patients remain on therapy for long-term benefits. Ongoing evaluation of these access pathways is essential for optimizing treatment outcomes.

Related Resources & Content

1. American Diabetes Association, ADA, 2026 -- Standards of Care in Diabetes—2026
2. Hamlet Gasoyan, DS, Michael B. Rothberg, MD, JAMA, 2026 -- The CMS BALANCE Model
3. New England Journal of Medicine, NEJM, 2023 -- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
4. PubMed, 2026 -- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists
5. Journal of Medical Internet Research (JMIR) — After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care
6. the analytical scientist — The Oral GLP‑1 Era Has Arrived 
7. the medicine maker — GLP-1 Analysis: Riding the Wave of Peptide Innovation
8. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care
9. The Oral GLP‑1 Era Has Arrived
10. GLP-1 Analysis: Riding the Wave of Peptide Innovation
11. The American Diabetes Association Releases “Standards of Care in Diabetes—2026” | American Diabetes Association
12. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine
13. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity - PubMed